Establishment of a structure-activity relationship of the 1H-imidazo[4,5-c]quinoline-based kinase inhibitor NVP-BEZ235 as a lead for African sleeping sickness

João D Seixas, Sandra A Luengo-Arratta, Rosario Diaz, Manuel Saldivia, Domingo I Rojas-Barros, Pilar Manzano, Silvia Gonzalez, Manuela Berlanga, Terry K Smith, Miguel Navarro*, Michael P Pollastri

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

30 Citations (Scopus)

Abstract

The compound NVP-BEZ235 (1) is a potent inhibitor of human phospoinositide-3-kinases (PI3Ks) and mammalian target of rapamycin (mTOR) that also showed high inhibitory potency against T. brucei cultures. With an eye towards using 1 as a starting point for anti-trypanosomal drug discovery, we report efforts to reduce host cell toxicity, improve the physicochemical properties and improve the selectivity profile over human kinases. In this work we have developed structure-activity relationships (SAR) for analogs of 1 and have prepared analogs of 1 with improved solubility properties and good predicted central nervous system exposure. In that way, we have identified 4e, 9, 16e and 16g as the most promising leads to date. We also report cell phenotype and phospholipidomic studies that suggest that these compounds exert their anti-trypanosomal effects, at least in part, by inhibition of lipid kinases.
Original languageEnglish
Pages (from-to)4834-4848
Number of pages15
JournalJournal of Medicinal Chemistry
Volume57
Issue number11
Early online date7 May 2014
DOIs
Publication statusPublished - 12 Jun 2014

Keywords

  • African sleeping sickness
  • Structure-activity relationship
  • Inhibitors
  • Phosphoinositol-kinase

Fingerprint

Dive into the research topics of 'Establishment of a structure-activity relationship of the 1H-imidazo[4,5-c]quinoline-based kinase inhibitor NVP-BEZ235 as a lead for African sleeping sickness'. Together they form a unique fingerprint.

Cite this